Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dipya IBS Care is a clinically tested, 100% Ayurvedic polyherbal formulation developed by Charak Pharma and marketed under its personal care and wellness brand, Vedistry. It is specifically designed to manage the chronic and unpredictable symptoms of Irritable Bowel Syndrome (IBS), including diarrhea-predominant (IBS-D) and mixed/alternating (IBS-M) patterns. The formulation contains a synergistic blend of traditional Ayurvedic herbs, including Kutaj (*Holarrhena antidysenterica*), Bilwamajja (*Aegle marmelos* / Bael Fruit Pulp), Sunthi (*Zingiber officinale* / Dry Ginger), Brahmi (*Bacopa monnieri*), Ativisha, and Musta (*Cyperus rotundus*). Dipya IBS Care works along the gut-brain axis to calm intestinal inflammation, reduce intestinal urgency, ease stress-triggered digestive spasms, and restore natural gut rhythm and regularity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dipya IBS Care.